The modulation of S1PR1 has been shown to regulate the lymphocytic migration without downregulating overall immune function, in contrast to other immunosuppressants historically used for IBD [12], and therefore has a favourable side-effect profile [13]. Here, S1PR1 is linked to inflammatory bowel disease.